Introducing Xpert® Xpress CoV-2/Flu/RSV plus* and Xpert® Xpress CoV-2 plus*

Enhanced gene coverage, plus the option of multiplex viral detection. When you need to know if it’s the flu, COVID-19, or RSV, choose a testing duo that delivers more. With our growing respiratory portfolio, Cepheid offers fast and accurate options to deliver more than results. Whatever your testing needs, Cepheid has you covered.

Coverage, plus
Accuracy, plus
Peace of mind

That’s the PCRplus advantage. From Cepheid

.

* These tests have not been FDA cleared or approved. These tests have been authorized by FDA under an EUA for use by authorized laboratories. Xpert Xpress CoV-2 plus has been authorized only for the detection of nucleic acids from SARS-CoV-2, and not for any other viruses or pathogens. Xpert Xpress CoV-2/Flu/RSV plus has been authorized only for the simultaneous qualitative detection and differentiation of nucleic acids from SARS-CoV-2, influenza A, influenza B, and respiratory syncytial virus (RSV), and not for any other viruses or pathogens. These tests are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

Access Product Resources

Xpert® Xpress CoV-2/Flu/RSV plus*

Meet the challenges of the ongoing pandemic with the confidence of a single test to detect and differentiate SARS-CoV-2, Flu A, Flu B, and RSV. Results for all four pathogens in just 36 minutes.

* These tests have not been FDA cleared or approved. These tests have been authorized by FDA under an EUA for use by authorized laboratories. Xpert Xpress CoV-2 plus has been authorized only for the detection of nucleic acids from SARS-CoV-2, and not for any other viruses or pathogens. Xpert Xpress CoV-2/Flu/RSV plus has been authorized only for the simultaneous qualitative detection and differentiation of nucleic acids from SARS-CoV-2, influenza A, influenza B, and respiratory syncytial virus (RSV), and not for any other viruses or pathogens. These tests are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
Access Product Resources Access Product Resources

Xpert® Xpress CoV-2 plus*

More testing options to support care. Designed with enhanced gene coverage to test symptomatic and asymptomatic patients. Rapid on-demand detection of SARS-CoV-2.

* This test has not been FDA cleared or approved; this test has been authorized by FDA under an EUA for use by authorized laboratories; this test has been authorized only for the simultaneous qualitative detection and differentiation of nucleic acids from SARS-CoV-2,  not for any other viruses or pathogens; and this test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
Access Product Resources Access Product Resources
For use under an Emergency Use Authorization in the United States.
* With early assay termination for positives when running SARS-CoV-2 only. Full run time is 36 min.
With early assay termination for positives. Full run time is 30 min.
See package insert for details; sample types may vary by system and regulatory status.
Learn About Cepheid GeneXpert® Systems